|Bid||3.7600 x 1300|
|Ask||4.0000 x 2200|
|Day's range||3.7596 - 4.0700|
|52-week range||2.3550 - 11.3300|
|Beta (5Y monthly)||1.64|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.88|
Even if it's not a huge purchase, we think it was good to see that Todd Brady, the CEO, President & Director of Aldeyra...
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
LEXINGTON, Mass., June 09, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies Global Healthcare Conference.